comparemela.com

Latest Breaking News On - Fda approval - Page 14 : comparemela.com

Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury

/PRNewswire/ Mission Therapeutics ("Mission" or the "Company"), a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, today.

United statesUnited kingdomSuhail nurbhaiPaul thompsonAnker lundemoseRoche venture fundDrug administrationMission therapeuticsIp groupPrnewswire mission therapeuticsInvestigational new drugAcute kidney injuryNorth americaChief executive officerChief medical officerChief scientific officer

Enfortumab Vedotin/Pembrolizumab Combo, Maintenance Avelumab Continue as Gold Standards in Metastatic Urothelial Cancer

Lance C. Pagliaro, MD, highlights updated data from the JAVELIN Bladder 100 and EV-103 trials in metastatic urothelial carcinoma, discusses their relevance for navigating the expanding treatment armamentarium for this disease, and outlines several future avenues for research.

United statesMayo clinic in rochesterPowlest sridharLancec pagliaroDepartment of oncologyAmerican urological association annual meetingDivision of medical oncologyUrological association annualMedical oncologyMayo clinicScience summitEnfortumab vedotinAsco annual meetingFda approvalAua meetingState of the science summit

Novartis reports success in phase 3 trial of drug for rare kidney disease

Novartis reports positive topline results from a Phase 3 trial of iptacopan, a drug to treat a rare kidney disease, C3 glomerulopathy.

Shreeram aradhye3 glomerulopathyKidney diseaseTopline resultsPhase 3 trialFda approval

Phathom s impending heartburn treatement given NDA by FDA

Millions of US adults suffering from heartburn associated with non-erosive-gastroesophageal-reflux-disease (GERD) could benefit from an impending treatment by Phathom Pharmaceuticals.

Azmi nabulsiPhathom pharmaceuticalsDrug administrationPrescription drug user fee actNew drug applicationClinical developmentMarkets amp regulationsAtient centricityPis active pharmaceutical ingredientsHasei iiPhase iii ivFda approvalFood and drug administrationPhathom pharmaceuticals

Sickle cell cure: FDA advisory committee approves 2 gene editing treatment therapies, including CRISPR

New FDA-approved therapy treatments that use genetic modification called CRISPR may lead to a sickle cell disease cure.

United kingdomUnited statesNicole verdunVertex pharmaceuticalsDrug administrationNobel prizeBluebird bioSickle cell cureGene editingFda approvalExa celFda advisory committeeSickle diseaseSickle cell diseaseWhat is sickle cellIckle cell crispr

vimarsana © 2020. All Rights Reserved.